Dyne Therapeutics (DYN) Stock Forecast & Price Target
Score
Dyne Therapeutics, Inc. price target
| DYN | |
|---|---|
| Low | $24.00 |
| Average | $35.20 |
| High | $50.00 |
| Upside vs current price | +105.1% |
The average target of $35.20 is +105.1% versus the current DYN price of $17.16.
Dyne Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 3 |
| Buy | 12 |
| Hold | 1 |
| Sell | 0 |
| Strong sell | 1 |
| Consensus | Buy |
17 analysts cover DYN.
Dyne Therapeutics, Inc. EPS and revenue estimates
The estimate table for the Dyne Therapeutics, Inc. keeps 2026 EPS $-3.61, 2027 EPS $-3.35, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-3.61 | $995,727 |
| 2027 | $-3.35 | $53.41M |
Is Dyne Therapeutics, Inc. a buy or sell?
Of the 17 analysts covering Dyne Therapeutics, Inc., 15 rate it a buy (3 strong buy and 12 buy), 1 rates it a hold, and 1 rates it a sell (0 sell and 1 strong sell).
The DYN consensus label is Buy, beside 15 buy-side ratings and 1 sell-side ratings.
The average target of $35.20 implies +105.1% versus the current price of $17.16.
the Dyne Therapeutics, Inc. closes with 15 buy-side ratings and 1 on the sell side. The headcount is Buy.
Reading the Dyne Therapeutics, Inc. forecast
Analysts are far apart on DYN. The published low is $24.00, the average is $35.20, and the high is $50.00.
From today's $17.16 print, the DYN average target is +105.1% away.
Most of the DYN coverage agrees: 15 of 17 analysts are on the buy side, 1 is at hold, and 1 is on the sell side, and the published consensus is Buy.
DYN picked up 2 downgrades in the recent window, against 0 upgrades.
Earnings estimates for DYN are rising: 2026 $-3.61, then 2027 $-3.35.
Coverage of DYN is broad at 17 analysts, and the average is a crowd rather than a single desk.
Dyne Therapeutics, Inc. forecast questions
What is the DYN price target?
The published range for DYN is $24.00 to $50.00, with an average of $35.20. That average is +105.1% versus the current price of $17.16.
Is Dyne Therapeutics, Inc. a buy or sell?
Of the 17 analysts covering Dyne Therapeutics, Inc., 15 rate it a buy, 1 rates it a hold, and 1 rates it a sell. The consensus is Buy, which for DYN is 15 on the buy side, 1 at hold, and 1 on the sell side.
What is the EPS estimate for Dyne Therapeutics, Inc.?
Analyst EPS estimates for Dyne Therapeutics, Inc.: 2026 $-3.61, 2027 $-3.35.
What is the revenue estimate for Dyne Therapeutics, Inc.?
Analyst revenue estimates for Dyne Therapeutics, Inc.: 2026 $995,727, 2027 $53.41M.
How many analysts cover DYN?
17 analysts cover DYN. Their consensus on DYN is Buy, across those 17.